retatrutide 2025 trial results 28.7% Weight Loss in New Study – Dr Brad Stanfield Weight loss with retatrutide as

Semaglutide and tirzepatide are FDA-approved prescription drugs, manufactured and distributed under controlled supply chains for clinical use

The FDA has explicitly stated that retatrutide cannot be used in compounding under federal law because it is not a component of an FDA-approved drug and has not been evaluated for safety and efficacy

Certain bacterial strains stimulate L-cells to produce more GLP-1 naturally

Clinical trials show that orforglipron can help people lose, on average, about 12% of their body weight

GLP-1s are not a shortcut theyre a scientific breakthrough that demands care, precision, and context, said Dr

For diabetes during pregnancy, insulin is the safest choice